Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications

Brian Godman, Björn Wettermark, Menno Van Woerkom, Jessica Fraeyman, Samantha Alvarez-Madrazo, Christian Berg, Iain Bishop, Anna Bucsics, Stephen Campbell, Alexander Finlayson, Jurij Fürst, Kristina Garuoliene, Harald Herholz, Marija Kalaba, Ott Laius, Jutta Piessnegger, Catherine Sermet, Ulrich Schwabe, Vera Vlahovic-Palcevski, Vanda Markovic-Pekovic & 4 others Luka Voncina, Kamila Malinowska, Corinne Zara, Lars L Gustafsson

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilization. However, considerable variation in their use and prices.

Objective: Assess the influence of multiple supply and demand-side initiatives across Europe for established medicines to enhance prescribing efficiency before a decision to prescribe a particular medicine. Subsequently utilize the findings to suggest potential future initiatives that countries could consider.

Method: An analysis of different methodologies involving cross national and single country retrospective observational studies on reimbursed use and expenditure of PPIs, statins, and renin-angiotensin inhibitor drugs among European countries.

Results: Nature and intensity of the various initiatives appreciably influenced prescribing behavior and expenditure, e.g., multiple measures resulted in reimbursed expenditure for PPIs in Scotland in 2010 56% below 2001 levels despite a 3-fold increase in utilization and in the Netherlands, PPI expenditure fell by 58% in 2010 vs. 2000 despite a 3-fold increase in utilization. A similar picture was seen with prescribing restrictions, i.e., (i) more aggressive follow-up of prescribing restrictions for patented statins and ARBs resulted in a greater reduction in the utilization of patented statins in Austria vs. Norway and lower utilization of patented ARBs vs. generic ACEIs in Croatia than Austria. However, limited impact of restrictions on esomeprazole in Norway with the first prescription or recommendation in hospital where restrictions do not apply. Similar findings when generic losartan became available in Western Europe.

Conclusions: Multiple demand-side measures are needed to influence prescribing patterns. When combined with supply-side measures, activities can realize appreciable savings. Health authorities cannot rely on a "spill over" effect between classes to affect changes in prescribing
Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalFrontiers in Pharmacology
Volume5
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Health Expenditures
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Austria
Norway
Esomeprazole
Croatia
Losartan
Angiotensins
Scotland
Renin
Pharmaceutical Preparations
Netherlands
Observational Studies
Prescriptions
Retrospective Studies
Medicine
Health
Growth

Cite this

Godman, Brian ; Wettermark, Björn ; Van Woerkom, Menno ; Fraeyman, Jessica ; Alvarez-Madrazo, Samantha ; Berg, Christian ; Bishop, Iain ; Bucsics, Anna ; Campbell, Stephen ; Finlayson, Alexander ; Fürst, Jurij ; Garuoliene, Kristina ; Herholz, Harald ; Kalaba, Marija ; Laius, Ott ; Piessnegger, Jutta ; Sermet, Catherine ; Schwabe, Ulrich ; Vlahovic-Palcevski, Vera ; Markovic-Pekovic, Vanda ; Voncina, Luka ; Malinowska, Kamila ; Zara, Corinne ; Gustafsson, Lars L. / Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications. In: Frontiers in Pharmacology. 2014 ; Vol. 5. pp. 1-9.
@article{a50a8b3d463e41119d368e42e28c6695,
title = "Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications",
abstract = "Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilization. However, considerable variation in their use and prices. Objective: Assess the influence of multiple supply and demand-side initiatives across Europe for established medicines to enhance prescribing efficiency before a decision to prescribe a particular medicine. Subsequently utilize the findings to suggest potential future initiatives that countries could consider. Method: An analysis of different methodologies involving cross national and single country retrospective observational studies on reimbursed use and expenditure of PPIs, statins, and renin-angiotensin inhibitor drugs among European countries. Results: Nature and intensity of the various initiatives appreciably influenced prescribing behavior and expenditure, e.g., multiple measures resulted in reimbursed expenditure for PPIs in Scotland in 2010 56{\%} below 2001 levels despite a 3-fold increase in utilization and in the Netherlands, PPI expenditure fell by 58{\%} in 2010 vs. 2000 despite a 3-fold increase in utilization. A similar picture was seen with prescribing restrictions, i.e., (i) more aggressive follow-up of prescribing restrictions for patented statins and ARBs resulted in a greater reduction in the utilization of patented statins in Austria vs. Norway and lower utilization of patented ARBs vs. generic ACEIs in Croatia than Austria. However, limited impact of restrictions on esomeprazole in Norway with the first prescription or recommendation in hospital where restrictions do not apply. Similar findings when generic losartan became available in Western Europe. Conclusions: Multiple demand-side measures are needed to influence prescribing patterns. When combined with supply-side measures, activities can realize appreciable savings. Health authorities cannot rely on a {"}spill over{"} effect between classes to affect changes in prescribing",
author = "Brian Godman and Bj{\"o}rn Wettermark and {Van Woerkom}, Menno and Jessica Fraeyman and Samantha Alvarez-Madrazo and Christian Berg and Iain Bishop and Anna Bucsics and Stephen Campbell and Alexander Finlayson and Jurij F{\"u}rst and Kristina Garuoliene and Harald Herholz and Marija Kalaba and Ott Laius and Jutta Piessnegger and Catherine Sermet and Ulrich Schwabe and Vera Vlahovic-Palcevski and Vanda Markovic-Pekovic and Luka Voncina and Kamila Malinowska and Corinne Zara and Gustafsson, {Lars L}",
year = "2014",
doi = "10.3389/fphar.2014.00106",
language = "English",
volume = "5",
pages = "1--9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",

}

Godman, B, Wettermark, B, Van Woerkom, M, Fraeyman, J, Alvarez-Madrazo, S, Berg, C, Bishop, I, Bucsics, A, Campbell, S, Finlayson, A, Fürst, J, Garuoliene, K, Herholz, H, Kalaba, M, Laius, O, Piessnegger, J, Sermet, C, Schwabe, U, Vlahovic-Palcevski, V, Markovic-Pekovic, V, Voncina, L, Malinowska, K, Zara, C & Gustafsson, LL 2014, 'Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications', Frontiers in Pharmacology, vol. 5, pp. 1-9. https://doi.org/10.3389/fphar.2014.00106

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications. / Godman, Brian; Wettermark, Björn; Van Woerkom, Menno; Fraeyman, Jessica; Alvarez-Madrazo, Samantha; Berg, Christian; Bishop, Iain; Bucsics, Anna; Campbell, Stephen; Finlayson, Alexander; Fürst, Jurij; Garuoliene, Kristina; Herholz, Harald; Kalaba, Marija; Laius, Ott; Piessnegger, Jutta; Sermet, Catherine; Schwabe, Ulrich; Vlahovic-Palcevski, Vera; Markovic-Pekovic, Vanda; Voncina, Luka; Malinowska, Kamila; Zara, Corinne; Gustafsson, Lars L.

In: Frontiers in Pharmacology, Vol. 5, 2014, p. 1-9.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications

AU - Godman, Brian

AU - Wettermark, Björn

AU - Van Woerkom, Menno

AU - Fraeyman, Jessica

AU - Alvarez-Madrazo, Samantha

AU - Berg, Christian

AU - Bishop, Iain

AU - Bucsics, Anna

AU - Campbell, Stephen

AU - Finlayson, Alexander

AU - Fürst, Jurij

AU - Garuoliene, Kristina

AU - Herholz, Harald

AU - Kalaba, Marija

AU - Laius, Ott

AU - Piessnegger, Jutta

AU - Sermet, Catherine

AU - Schwabe, Ulrich

AU - Vlahovic-Palcevski, Vera

AU - Markovic-Pekovic, Vanda

AU - Voncina, Luka

AU - Malinowska, Kamila

AU - Zara, Corinne

AU - Gustafsson, Lars L

PY - 2014

Y1 - 2014

N2 - Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilization. However, considerable variation in their use and prices. Objective: Assess the influence of multiple supply and demand-side initiatives across Europe for established medicines to enhance prescribing efficiency before a decision to prescribe a particular medicine. Subsequently utilize the findings to suggest potential future initiatives that countries could consider. Method: An analysis of different methodologies involving cross national and single country retrospective observational studies on reimbursed use and expenditure of PPIs, statins, and renin-angiotensin inhibitor drugs among European countries. Results: Nature and intensity of the various initiatives appreciably influenced prescribing behavior and expenditure, e.g., multiple measures resulted in reimbursed expenditure for PPIs in Scotland in 2010 56% below 2001 levels despite a 3-fold increase in utilization and in the Netherlands, PPI expenditure fell by 58% in 2010 vs. 2000 despite a 3-fold increase in utilization. A similar picture was seen with prescribing restrictions, i.e., (i) more aggressive follow-up of prescribing restrictions for patented statins and ARBs resulted in a greater reduction in the utilization of patented statins in Austria vs. Norway and lower utilization of patented ARBs vs. generic ACEIs in Croatia than Austria. However, limited impact of restrictions on esomeprazole in Norway with the first prescription or recommendation in hospital where restrictions do not apply. Similar findings when generic losartan became available in Western Europe. Conclusions: Multiple demand-side measures are needed to influence prescribing patterns. When combined with supply-side measures, activities can realize appreciable savings. Health authorities cannot rely on a "spill over" effect between classes to affect changes in prescribing

AB - Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilization. However, considerable variation in their use and prices. Objective: Assess the influence of multiple supply and demand-side initiatives across Europe for established medicines to enhance prescribing efficiency before a decision to prescribe a particular medicine. Subsequently utilize the findings to suggest potential future initiatives that countries could consider. Method: An analysis of different methodologies involving cross national and single country retrospective observational studies on reimbursed use and expenditure of PPIs, statins, and renin-angiotensin inhibitor drugs among European countries. Results: Nature and intensity of the various initiatives appreciably influenced prescribing behavior and expenditure, e.g., multiple measures resulted in reimbursed expenditure for PPIs in Scotland in 2010 56% below 2001 levels despite a 3-fold increase in utilization and in the Netherlands, PPI expenditure fell by 58% in 2010 vs. 2000 despite a 3-fold increase in utilization. A similar picture was seen with prescribing restrictions, i.e., (i) more aggressive follow-up of prescribing restrictions for patented statins and ARBs resulted in a greater reduction in the utilization of patented statins in Austria vs. Norway and lower utilization of patented ARBs vs. generic ACEIs in Croatia than Austria. However, limited impact of restrictions on esomeprazole in Norway with the first prescription or recommendation in hospital where restrictions do not apply. Similar findings when generic losartan became available in Western Europe. Conclusions: Multiple demand-side measures are needed to influence prescribing patterns. When combined with supply-side measures, activities can realize appreciable savings. Health authorities cannot rely on a "spill over" effect between classes to affect changes in prescribing

U2 - 10.3389/fphar.2014.00106

DO - 10.3389/fphar.2014.00106

M3 - Article

VL - 5

SP - 1

EP - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

ER -